Advertisement
Screener

PALATIN TECHNOLOGIES, INC. (PTN) Foreign Currency Transaction Gain (Loss), Unrealized

2.0 / 5 stars · 28/71 Roast Me

PALATIN TECHNOLOGIES, INC. Foreign Currency Transaction Gain (Loss), Unrealized

PALATIN TECHNOLOGIES, INC. (PTN) reported Foreign Currency Transaction Gain (Loss), Unrealized of $0 for the 3-month period ending 2025-09-30, per its 10-Q filed 2025-11-14.

Financial Statements › Cash Flow › Operating Activities

us-gaap:ForeignCurrencyTransactionGainLossUnrealized · last filed 2026-05-13

  • PALATIN TECHNOLOGIES, INC. foreign currency transaction gain (loss), unrealized for the quarter ending 2025-09-30 was $0.00.
  • PALATIN TECHNOLOGIES, INC. foreign currency transaction gain (loss), unrealized for the quarter ending 2025-06-30 was $15.85K.
  • PALATIN TECHNOLOGIES, INC. foreign currency transaction gain (loss), unrealized for the quarter ending 2025-03-31 was -$27.90K, a 112.94% decline year-over-year.
  • PALATIN TECHNOLOGIES, INC. foreign currency transaction gain (loss), unrealized for the quarter ending 2024-12-31 was $143.60K.
  • PALATIN TECHNOLOGIES, INC. foreign currency transaction gain (loss), unrealized for fiscal 2025 was -$50.00, a 100.08% decline from fiscal 2024.
  • PALATIN TECHNOLOGIES, INC. foreign currency transaction gain (loss), unrealized for fiscal 2024 was $59.75K.
  • PALATIN TECHNOLOGIES, INC. foreign currency transaction gain (loss), unrealized for fiscal 2023 was -$429.97K.
  • PALATIN TECHNOLOGIES, INC. foreign currency transaction gain (loss), unrealized for fiscal 2022 was -$389.87K.
Period endForeign Currency Transaction Gain (Loss), Unrealized 3 monthForeign Currency Transaction Gain (Loss), Unrealized 6 monthForeign Currency Transaction Gain (Loss), Unrealized 9 monthForeign Currency Transaction Gain (Loss), Unrealized 12 monthForeign Currency Transaction Gain (Loss), Unrealized 12 month as first filed
2025-09-30$0.00
10-Q · filed 2025-11-14
$15.85K
derived: sum of 2 quarters · filed 2025-11-14
-$12.05K
derived: sum of 3 quarters · filed 2026-05-13
$131.55K
derived: sum of 4 quarters · filed 2026-05-13
2025-06-30$15.85K
derived: 10-K 12 month − 10-Q 9 month · filed 2025-09-23
-$12.05K
derived: sum of 2 quarters · filed 2026-05-13
$131.55K
derived: sum of 3 quarters · filed 2026-05-13
-$50.00
10-K · filed 2025-09-23
2025-03-31-$27.90K
derived: 10-Q 9 month − 10-Q 6 month · filed 2026-05-13
$115.70K
derived: sum of 2 quarters · filed 2026-05-13
-$15.90K
10-Q · filed 2026-05-13
-$24.80K
derived: sum of 4 quarters · filed 2026-05-13
2024-12-31$143.60K
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-02-17
$12.00K
10-Q · filed 2026-02-17
$3.10K
derived: sum of 3 quarters · filed 2026-02-17
$218.70K
derived: sum of 4 quarters · filed 2026-02-17
2024-09-30-$131.60K
10-Q · filed 2025-11-14
-$140.50K
derived: sum of 2 quarters · filed 2025-11-14
$75.10K
derived: sum of 3 quarters · filed 2025-11-14
-$231.60K
derived: sum of 4 quarters · filed 2025-11-14
2024-06-30-$8.90K
derived: 10-K 12 month − 10-Q 9 month · filed 2025-09-23
$206.70K
derived: sum of 2 quarters · filed 2025-09-23
-$100.00K
derived: sum of 3 quarters · filed 2025-09-23
$59.75K
10-K · filed 2025-09-23
2024-03-31$215.60K
10-Q · filed 2024-05-15
-$91.10K
derived: sum of 2 quarters · filed 2024-05-15
$68.65K
10-Q · filed 2025-05-14
-$9.20K
derived: sum of 4 quarters · filed 2024-09-30
2023-12-31-$306.70K
10-Q · filed 2024-02-14
-$146.95K
10-Q · filed 2024-02-14
-$224.80K
derived: sum of 3 quarters · filed 2024-09-30
-$302.06K
derived: sum of 4 quarters · filed 2024-09-30
2023-09-30$159.75K
10-Q · filed 2023-11-14
$81.90K
derived: sum of 2 quarters · filed 2024-09-30
$4.63K
derived: sum of 3 quarters · filed 2024-09-30
-$688.60K
derived: sum of 4 quarters · filed 2024-09-30
2023-06-30-$77.85K
derived: 10-K 12 month − 10-Q 9 month · filed 2024-09-30
-$155.12K
derived: sum of 2 quarters · filed 2024-09-30
-$848.35K
derived: sum of 3 quarters · filed 2024-09-30
-$429.97K
10-K · filed 2024-09-30
$429.97K
10-K · filed 2023-09-28
2023-03-31-$77.27K
10-Q · filed 2024-05-15
-$770.50K
derived: sum of 2 quarters · filed 2024-05-15
-$352.12K
10-Q · filed 2024-05-15
-$805.99K
derived: sum of 4 quarters · filed 2024-05-15
2022-12-31-$693.23K
10-Q · filed 2024-02-14
-$274.86K
10-Q · filed 2024-02-14
-$728.72K
derived: sum of 3 quarters · filed 2024-02-14
-$538.00K
derived: sum of 4 quarters · filed 2024-02-14
2022-09-30$418.38K
10-Q · filed 2023-11-14
-$35.49K
derived: sum of 2 quarters · filed 2023-11-14
$155.23K
derived: sum of 3 quarters · filed 2023-11-14
2022-06-30-$453.87K
derived: 10-K 12 month − 10-Q 9 month · filed 2023-09-28
-$263.15K
derived: sum of 2 quarters · filed 2023-09-28
-$389.87K
10-K · filed 2023-09-28
2022-03-31$190.72K
10-Q · filed 2023-05-15
$64.00K
10-Q · filed 2023-05-15
2021-12-31-$126.72K
10-Q · filed 2023-02-14
2021-03-31$8.75K
10-Q · filed 2022-05-16

Similar stocks

Stock NameCountryMarket CapPE Ratio
Lipocine Inc. (LPCN)United States$0.017B-1.79
Allarity Therapeutics, Inc. (ALLR)United States$0.017B-1.66
Pasithea Therapeutics Corp. (KTTA)United States$0.017B-0.81
Biofrontera Inc. (BFRI)United States$0.018B-2.13
Korsana Biosciences, Inc. (CYCN)United States$0.016B
Citius Pharmaceuticals, Inc. (CTXR)United States$0.016B-133.06
Rocket One Inc. (RKTO)United States$0.019B
Shuttle Pharmaceuticals Holdings, Inc. (SHPH)United States$0.019B-0.31
Lantern Pharma Inc. (LTRN)United States$0.015B-2.87
Anebulo Pharmaceuticals, Inc. (ANEB)United States$0.015B